Raffaella Cascella

Dr. Raffaella Cascella

Medical Genetics Laboratory, Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2014 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
Raffaella CascellaRaffaella Cascella
Raffaella Cascella
MRMichele Ragazzo
Michele Ragazzo
CSClaudia Strafella
Claudia Strafella
FMFilippo Missiroli
Filippo Missiroli
PBPaola Borgiani
Paola Borgiani
EGEmiliano Giardina
Emiliano Giardina
Age-related macular degeneration (AMD) is a progressive neurodegenerative disease that affects approximately 8.7% of elderly people worldwide (>55 years old). AMD is characterized by a multifactorial aetiology that involves several genetic and environmental risk factors (genes, ageing, smoking, family history, dietary habits, oxidative stress, and hypertension). In particular, ageing and cigarette smoking (including oxidative compounds and reactive oxygen species) have been shown to significantly increase susceptibility to the disease. Furthermore, different genes (CFH, CFI, C2, C3, IL-6, IL-8,andARMS2) that play a crucial role in the inflammatory pathway have been associated with AMD risk. Several genetic and molecular studies have indicated the participation of inflammatory molecules (cytokines and chemokines), immune cells (macrophages), and complement proteins in the development and progression of the disease. Taking into consideration the genetic and molecular background, this review highlights the genetic role of inflammatory genes involved in AMD pathogenesis and progression.

3 July 2020 in Genes
Verified
Journal Article
Open access
PDF file
CSClaudia Strafella
Claudia Strafella
VCValerio Caputo
Valerio Caputo
ATAndrea Termine
Andrea Termine
Shila BaratiShila Barati
Shila Barati
SGStefano Gambardella
Stefano Gambardella
Raffaella CascellaRaffaella Cascella
Raffaella Cascella
Angiotensin-converting enzyme 2 (ACE2) has been recognized as the entry receptor of the novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). Structural and sequence variants in ACE2 gene may affect its expression in different tissues and determine a differential response to SARS-Cov-2 infection and the COVID-19-related phenotype. The present study investigated the genetic variability of ACE2 in terms of single nucleotide variants (SNVs), copy number variations (CNVs), and expression quantitative loci (eQTLs) in a cohort of 268 individuals representative of the general Italian population. The analysis identified five SNVs (rs35803318, rs41303171, rs774469453, rs773676270, and rs2285666) in the Italian cohort. Of them, rs35803318 and rs2285666 displayed a significant different frequency distribution in the Italian population with respect to worldwide population. The eQTLs analysis located in and targeting ACE2 revealed a high distribution of eQTL variants in different brain tissues, suggesting a possible link between ACE2 genetic variability and the neurological complications in patients with COVID-19. Further research is needed to clarify the possible relationship between ACE2 expression and the susceptibility to neurological complications in patients with COVID-19. In fact, patients at higher risk of neurological involvement may need different monitoring and treatment strategies in order to prevent severe, permanent brain injury.

31 October 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
VCValerio Caputo
Valerio Caputo
CSClaudia Strafella
Claudia Strafella
ATAndrea Termine
Andrea Termine
ADAnnunziata Dattola
Annunziata Dattola
SMSara Mazzilli
Sara Mazzilli
Raffaella CascellaRaffaella Cascella
Raffaella Cascella
Psoriasis and psoriatic arthritis are multifactorial chronic disorders whose etiopathogenesis essentially derives from the alteration of several signalling pathways and the co‐occurrence of genetic, epigenetic and non‐genetic susceptibility factors that altogether affect the functional and structural property of the skin. Although shared and differential susceptibility genes and molecular pathways are known to contribute to the onset of pathological phenotypes, further research is needed to dissect the molecular causes of psoriatic disease and its progression towards Psoriatic Arthritis. This review will therefore be addressed to explore differences and similarities in the etiopathogenesis and progression of both disorders, with a particular focus on genes involved in the maintenance of the skin structure and integrity (keratins and collagens), modulation of patterns of recognition (through Toll‐like receptors and dectin‐1) and immuno‐inflammatory response (by NLRP3‐dependent inflammasome) to microbial pathogens. In addition, special emphasis will be given to the contribution of epigenetic elements (methylation pattern, non‐coding RNAs, chromatin modifiers and 3D genome organization) to the etiopathogenesis and progression of psoriasis and psoriatic arthritis. The evidence discussed in this review highlights how the knowledge of patients' clinical and (epi)genomic make‐up could be helpful for improving the available therapeutic strategies for psoriasis and psoriatic arthritis treatment.

10 September 2021 in Genes
Verified
Journal Article
Open access
PDF file
VCValerio Caputo
Valerio Caputo
CSClaudia Strafella
Claudia Strafella
Terenzio CosioTerenzio Cosio
Terenzio Cosio
CLCaterina Lanna
Caterina Lanna
Elena CampioneElena Campione
Elena Campione
Raffaella CascellaRaffaella Cascella
Raffaella Cascella
Pharmacogenomic studies allowed the reasons behind the different responses to treatments to be understood. Its clinical utility, in fact, is demonstrated by the reduction in adverse drug reaction incidence and the improvement of drug efficacy. Pharmacogenomics is an important tool that is able to improve the drug therapy of different disorders. In particular, this review will highlight the current pharmacogenomics knowledge about biologics and small-molecule treatments for psoriasis. To date, studies performed on genes involved in the metabolism of biological drugs (tumor necrosis factor inhibitors and cytokines inhibitors) and small molecules (apremilast, dimethyl fumarate, and tofacitinib) have provided conflicting results, and further investigations are necessary in order to establish a set of biomarkers to be introduced into clinical practice.

16 September 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Raffaella CascellaRaffaella Cascella
Raffaella Cascella
CSClaudia Strafella
Claudia Strafella
CGChiara Germani
Chiara Germani
GNGiuseppe Novelli
Giuseppe Novelli
FRFederico Ricci
Federico Ricci
EGEmiliano Giardina
Emiliano Giardina
The sight is one of the five senses allowing an autonomous and high-quality life, so that alterations of any ocular component may result in several clinical phenotypes (from conjunctivitis to severe vision loss and irreversible blindness). Most parts of clinical phenotypes have been significantly associated with mutations in genes regulating the normal formation and maturation of the anterior segments of the eye. Among the eye anterior segment disorders, special attention is given to Glaucoma as it represents one of the major causes of bilateral blindness in the world, with an onset due to Mendelian or multifactorial genetic-causative traits. This review will point out the attention on the Primary Congenital Glaucoma (PCG), which is usually transmitted according to an autosomal-recessive inheritance pattern. Taking into consideration the genetic component of the PCG, it is possible to observe a strong heterogeneity concerning the disease-associated loci (GLC3), penetrance defects, and expressivity of the disease. Given the strong PGC heterogeneity, pre- and posttest genetic counseling plays an essential role in the achievement of an appropriate management of PCG, in terms of medical, social, and psychological impact of the disease.

12 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Raffaella CascellaRaffaella Cascella
Raffaella Cascella
CSClaudia Strafella
Claudia Strafella
GLGiuliana Longo
Giuliana Longo
MRMichele Ragazzo
Michele Ragazzo
LMLaura Manzo
Laura Manzo
EGEmiliano Giardina
Emiliano Giardina
Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants